Cure My Disease

Don't miss your cure!

 Log in / Sign up

Four-in-One imaging may predict breast cancer treatment success

NCT ID NCT06879704

Knowledge-focused Sponsor: Centre Henri Becquerel Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether combining four types of scans (ultrasound, mammography, MRI, and PET-CT) can accurately predict if triple-negative breast cancer has been completely eliminated by chemotherapy and immunotherapy. Researchers will also check blood markers to identify which patients benefit most or are at higher risk for side effects. About 115 adults aged 18-75 with early-stage triple-negative breast cancer will participate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 115 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Nov 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed informed consent * Patient with histologically proven TNBC * Indication for neo-adjuvant chemo-immunotherapy treatment * Age between 18 and 75 * Affiliated or beneficiary of a social protection scheme Exclusion Criteria: * Pregnant or breast-feeding women * Contraindication to immunotherapy * Inflammatory breast cancer (T4d) * Metastatic patients * Allergies to iodine or gadolinium * Patient with an augmentation prosthesis (for angiography/mammography) * Claustrophobic patients * Renal contraindication to contrast products according to SFR-CIRTACI * Ferromagnetic material * Uncontrolled diabetes (blood glucose \>10 mmol/L) * Patient unable to understand the study for any reason or to comply with the constraints of the trial (language, psychological, geographical problems, etc.). * Patient under guardianship, curatorship or safeguard of justice

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Triple negative breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Triple negative breast cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Henri Becquerel

    RECRUITING

    Rouen, 76038, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.